Remove Allergies Remove Bioassay Remove Gene Therapy Remove Licensing
article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Peter O’Callaghan, PhD, Head of Expression System Sciences, Biologics and Licensing, Lonza, on: ‘Solve bispecific heavy-light chain mispairing with bYlok technology’. Anthony Stajduhar, Director of Global Business Development, Business Development, Rapid Novor, on: ‘Antibody discovery dead ends and new approaches’.